Francesca Barone
@baroneExpMed
Clinician scientist in love with experimental medicine.
Great day for @CandelTx !!!! linkedin.com/posts/francesc…
Join our investor conference call on Tuesday, June 3 at 1:00 PM ET following our #ASCO25 presentation. Our management team & leading prostate cancer specialists will discuss our phase 3 CAN-2409 results. Find more details here: ir.candeltx.com/news-releases/… $CADL #ProstateCancer
Candel Therapeutics is set to host a webcast and conference call on Tuesday, June 3, 2025, at 1:00 PM ET. The event will delve into the promising phase 3 clinical results for CAN-2409 in localized, intermediate-to-high risk prostate cancer. These results showcased a notable 30%…
New in @NeuroOnc! Our phase 1b trial of CAN-2409 + nivolumab in newly diagnosed high-grade glioma shows promising safety & survival data with immune activation supporting CAN-2409's pan-tumor potential. Read more: ir.candeltx.com/news-releases/… $CADL
Combination of surgical upfront immunotherapy with aglatimagene besadenovec (CAN-2409), followed by chemoradiation and then adjuvant nivolumab for newly diagnosed glioblastoma (Wen et al. March 2025, @NeuroOnc). @EAChiocca & @paulpetertak
The collaboration between Candel Therapeutics and IDEA Pharma comes at a critical time as we prepare for our BLA submission for CAN-2409 in prostate cancer. Candel will gain access to a dedicated team of experts with extensive experience in oncology commercialization and…
Molecular and spatial analysis of tertiary lymphoid structures in Sjogren’s syndrome nature.com/articles/s4146… @NatureComms @baroneExpMed
Manufacturing. While we continued to advance analytical development and comparability studies successfully, and locked the process, we did not want to spend tens of millions of $$ on large scale manufacturing before data read out - a concept that we call dynamic portfolio…
We hope we will deliver the data and regulatory approvals in prostate cancer to enable a paradigm shift in how these patients will be treated in the future. #CandelTherapeutics #viral #immunotherapy #CAN-2409 $CADL proactiveinvestors.com/companies/news…
Late stage melanoma represents a life threatening unmet clinical need. Come and visit our poster during SITC to discuss our plans to leverage our first in class viral immunotherapy CAN-3110 to fight this terrible disease.
Our team is presenting a poster on CAN-3110’s activity in a model of #melanoma at @sitcancer 39th Annual Meeting! See the details here: ir.candeltx.com/news-releases/… #SITC24 $CADL
Safe and feasible intratumoral CAN-2409 delivery on outpatient basis can reinvigorate immune response in ICI refractory #NSCLC and extend survival. @CharuAggarwalMD @Perlmutter_CC @nyulangone #ASCO24
Looking forward to presenting our data on intratumoral therapy in #NSCLC - evidence that we can overcome IO resistance and extend the tail of the curve. Check out our abstract # 8634 @StermanDaniel @PennMedicine @PennCancer @PennMDForum @ASCO #ASCO24
Posting comments about the interpretation of clinical trial data comes with a responsibility to get it absolutely right, especially as it relates to cancer patients who are urgently waiting for better treatments. Let's dissect why this post was misleading. A thread.
$CADL's data set has multiple red flags: -OS without a control arm is meaningless, the term "improved survival" in the PR is misleading - No objective responses - Evaluable population is 60% of enrolled patients (and we know the other 40% did much worse because ITT OS is lower)…
President and CEO,@paulpetertak, MD, PhD, FMedSci, CSO @baroneExpMed, MD, PhD, and VP of Finance & Corporate Controller, Charles Schoch are kicking off 2024 at the 42nd Annual @JPMorgan Healthcare conference. Be sure to say hello! #JPMorgan2024 #JPM24